RIA
ORMP icon

Regal Investment Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

Regal Investment Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-84
Closed – – 690
2015
Q3 		$0 Buy
+84
New +$528 ﹤0.01% 1088

Other funds holding ORMP

TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regal Investment Advisors's ORMP Position: Q4 2015 in Review

Regal Investment Advisors sold out of Oramed Pharmaceuticals (ORMP) in Q4 2015, closing a stake of 84 shares.

Regal Investment Advisors first reported a position in ORMP in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 26 funds tracked by Wall St. Rank hold ORMP as of Q4 2015.

  • Regal Investment Advisors reported no remaining Oramed Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Regal Investment Advisors sold 84 Oramed Pharmaceuticals shares in Q4 2015.
  • Regal Investment Advisors first reported a position in Oramed Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Regal Investment Advisors's Oramed Pharmaceuticals position peaked at $0 in Q3 2015.
  • 26 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2015.

Based on Regal Investment Advisors's 13F filing for Q4 2015, filed 8 Feb 2016.